Axsome Therapeutics vs Oruka Therapeutics
Axsome Therapeutics (AXSM), health care, and Oruka Therapeutics (ORKA), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Axsome Therapeutics is worth $7.2B on the stock market and Oruka Therapeutics $6.5B: Axsome Therapeutics is valued at 9% more. Over the past year Axsome Therapeutics's share price has moved -7.10% and Oruka Therapeutics's +262%.
Key facts
- Axsome Therapeutics market value
- $7.2B
- Oruka Therapeutics market value
- $6.5B
- Axsome Therapeutics revenue
- $638.5MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Axsome Therapeutics | Oruka Therapeutics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $7.2Bhigher | $6.5Blower |
| Revenue | $638.5M | — |
| Earnings | -$183.2Mlower | -$105.4Mhigher |
| Employees | 1,390higher | 68lower |
| Total assets | $689.8Mhigher | $488.6Mlower |
| Valuation | ||
| P/E | — | — |
| P/S | 11.2 | — |
| P/B | 67.8higher | 5.4lower |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | -26.1% | — |
| Balance sheet | ||
| Net assets | $88.3Mlower | $471.9Mhigher |
| Total liabilities | $601.5Mhigher | $16.7Mlower |
| Total debt | $187.7M | — |
| Cash on hand | $322.9Mhigher | $46.9Mlower |
| Price change | ||
| Today | -0.77%higher | -2.94%lower |
| 1 year | -7.10%lower | +262%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Axsome Therapeutics only (0)
None of the tracked investors.
Oruka Therapeutics only (3)
- Peter Kolchinsky1.3%
- Andreas Halvorsen0.4%
- Polen Capital team<0.1%
Percentages are each holding's share of that investor's reported portfolio. Who owns AXSM · Who owns ORKA
More on Axsome Therapeutics
Further comparisons
Axsome Therapeutics against its closest peers
Oruka Therapeutics against its closest peers
Learn
Questions and answers
Which is bigger, Axsome Therapeutics or Oruka Therapeutics?
By market value, Axsome Therapeutics is the larger: $7.2B against $6.5B for Oruka Therapeutics.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Axsome Therapeutics and Oruka Therapeutics?
None of the tracked superinvestors holds both in their latest 13F filing. 0 hold Axsome Therapeutics and 3 hold Oruka Therapeutics.
Cite this page
Funkfolio, “Axsome Therapeutics vs Oruka Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/axsm-vs-orka
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.